Annual report [Section 13 and 15(d), not S-K Item 405]

Segment Information - Schedule of financial information regularly reviewed and used by the CODM (Details)

v3.26.1
Segment Information - Schedule of financial information regularly reviewed and used by the CODM (Details) - USD ($)
 12 Months Ended
Feb. 21, 2025
Dec. 31, 2025
Dec. 31, 2024
Research and development (excluding share-based compensation) expense:      
PAH [1]   $ 22,453,185 $ 1,672,869
Parkinson's disease   647,242 9,333,359
Other research and development   1,219,560 1,512,151
Selling, general and administrative (excluding stock-based compensation)   13,718,314 7,930,072
Change in fair value contingent consideration $ (4,435,443) (1,373,942) 0
Stock-based compensation expense   15,309,924 8,140,617
Total costs and expenses   51,974,283 28,589,068
Loss from operations   (51,974,283) (28,589,068)
Interest income   3,715,094 1,069,182
Net loss   $ (48,259,189) $ (27,519,886)
[1] This amount includes a one-time (non-cash) charge of $7.4 million for the acquired IPR&D related to the CorHepta acquisition during the year ended December 31, 2025.